Novartis AG (NVS) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Novartis AG stock price
Novartis AG latest news:
Novartis launches heart drug counter-offensive
ZURICH, Nov 13 (Reuters) - Novartis plans to plow
through doubts over its canakinumab drug by asking regulators
this year to approve the medicine as a treatment for a group of
heart attack survivors that the Swiss drugmaker says is most
likely to benefit.
Novartis posts eye drug data amid play for Eylea's turf
Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
BRIEF-Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis
Advanced Accelerator Applications Sa(AAAP). * Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis. * Novartis will make cash tender offer to acquire all outstanding shares of co, including ADS, for $41 a share and $82 per ADS. * Deal represents 47 percent premium to 30 volume-weighted trading days prior to unaffected share price on nasdaq on Sept 27.
BRIEF-Ophthotech recieves termination notice from Novartis Pharma
* Ophthotech-On oct 24, co received from Novartis Pharma
notice terminating Licensing & Commercialization Agreement
between parties dated May 19, 2014
Source text : (http://bit.ly/2gPty5O)
Further company coverage:
Novartis boosts third-quarter profit, pushes Alcon decision to 2019
Novartis's third-quarter core net income rose 4 percent at constant currencies, beating expectations.
BRIEF-Novartis CEO: Alcon spinoff 'probably direction we are headed' - CNBC
* Ceo says wants to time alcon exit when market is strong,
expects strong market to continue - cnbc
BRIEF-Novartis CEO: Novartis shareholders would get Alcon shares in listing
* CEO Joe Jimenez says expects U.S. price pressure on
generics business to remain
Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018
Novartis AG NVS announced that its Chief Executive Officer CEO Joseph Jimenez will step down from his position in 2018 Vasant Narasimhan M D Global Head of Drug Development and Chief Medical Officer will replace him effective Feb 1 2018 Narasimhan is a member of the Executive
BRIEF-Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017
* Novartis Pharma AG reports a 6.6 percent passive stake in
Xoma Corp as of august 24, 2017 - SEC filing
Source text for Eikon: (http://bit.ly/2gEet2Y)
Further company coverage:
Novartis CEO Jimenez to step down early next year
Novartis says CEO Joseph Jimenez will step down early next year and be replaced by fellow American Vasant Narasimhan, a longtime manager with the Swiss pharmaceutical company
Novartis's Jimenez stepping down, Narasimhan named new CEO
ZURICH (Reuters) - Novartis Chief Executive Joseph Jimenez will retire in 2018, with chief drug developer Vasant Narasimhan taking over as CEO starting in February, the Swiss drugmaker said on Monday.
Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap
The cancer treatment industry is celebrating a massive victory on Wednesday as Novartis NVS received approval for its innovative new lymphoblastic leukemia treatment making it the first approved CAR T therapy in the world After achieving unprecedented results in patients with this deadly
BRIEF-Novartis receives FDA approval for CAR-T cell therapy Kymriah
* Novartis receives first ever FDA approval for a CAR-T cell
therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and
young adults with B-cell ALL that is refractory or has relapsed
at least twice
Source text for Eikon:
Further company coverage:
Biotech stocks rally, ETF on track for third straight daily gain
Biotechnology stocks rallied on Wednesday, with one of the biggest exchange-traded funds dedicated to the sector on track for its third straight daily advance. The iShares Nasdaq Biotechnology ETF gained 1.3%, bringing its week-to-date rise to 3.6%. Among the biggest gainers in the sector, Gilead Sciences Inc. popped 5.6%, bringing its gain over the past three months to 23.7%. The stock is on track for its largest percentage gain since November, as well as its highest close since September 2016. Separately, Incyte Corp. added 4.5% while BioMarin Pharmaceutical Inc. advanced 4.8%. Biogen Inc. gained 2.4% while Regeneron Pharmaceuticals Inc. was up 2%. On the downside within the pharmaceutical sector, U.S.-listed shares of Novartis AG were down 1%. The company's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Novartis AG's CAR-T cell therapy for leukemia approved by FDA in 'historic action'; price to be based on outcomes
Novartis AG's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia. CAR-T, or chimeric antigen receptor T-cell therapy, uses a patient's immune T-cells and re-engineers them to better fight cancer. As such, each dose of Kymriah is customized to the individual patient's T-cells through genetic modification. Novartis said on Wednesday that it will work with the Centers for Medicare and Medicaid Services so medicine prices can be "based on the clinical outcomes achieved, which would eliminate inefficiencies from the health care system." For Kymriah, Novartis is also working with CMS "to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month." Novartis did not give any specifics as to what the price range might be. Even before Novartis' Kymriah was approved, there was concern about pricing of the new therapy, given that new therapies are typically priced based on level of innovation and cancer is a particularly expensive area. On Wednesday, the FDA also expanded approval of Roche's Genentech's rheumatoid arthritis drug Actemra to treat CAR-T cell-induced cytokine release syndrome, which consists of high fever and flu-like symptoms and can be life-threatening; nearly 70% of patients had CRS completely resolved in two weeks using one or two doses of Actemra, the FDA said. Kite Pharma, which is also working in the CAR-T space, has also been racing to gain FDA approval; the biotech's $11 billion acquisition by Gilead Sciences Inc. was reported earlier this week. Gilead shares surged 5.5% in extremely heavy midday trade. Novartis shares declined 1% in heavy midday trade. Novartis shares have risen 2.8% over the last three months, compared with a 1.6% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Novartis gene therapy for leukemia wins U.S. approval
Aug 30 (Reuters) - The U.S. Food and Drug Administration
(FDA) on Wednesday approved Novartis AG's
keenly anticipated leukemia treatment, marking the first gene
therapy approval in the United States.
UPDATE 1-Novartis hopeful for novel heart drug, despite 'modest' benefit
* Novartis plans Q4 filing with regulators
(Adds analyst comment on pricing)
Novartis (NVS) Receives EC Approval for Breast Cancer Drug
Novartis AG NVS announced that the European Commission EC has approved breast cancer drug Kisqali ribociclib The EC approved the drug in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive human epidermal growth factor receptor
Novartis picks retail expert for new role of digital chief
LONDON, Aug 24 (Reuters) - Novartis has appointed a
senior retail expert to the new post of chief digital officer,
following a similar move by GlaxoSmithKline last month,
underscoring how drugmakers are grappling with the impact of new
Novo Nordisk A/SNVO
NQ Mobile Inc.NQ
Nu Skin EnterprisesNUS
Nustar Energy L.P.NS